-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Previous studies have suggested that the first 4 weeks after initiation and cessation of opioid agonist therapy for opioid dependence are associated with an increased risk of all-cause mortality and overdose
.
To investigate whether the rates of self-harm and suicide differ between people receiving opioid agonist therapy during initiation, cessation, and the remainder of time with and without treatment, experts from Population Health Sciences, University of Bristol School of Medicine, UK, conducted a correlation The study, the results were published in the journal Lancet Psychiatry
Previous studies have suggested that the first 4 weeks after initiation and cessation of opioid agonist therapy for opioid dependence are associated with an increased risk of all-cause mortality and overdose
Rates and adjusted hazard ratios (aRR) for hospital admissions for self-harm and suicide deaths were subsequently estimated, comparing time during and after treatment, and comparing the stable period of treatment with the remainder of initiating treatment, stopping treatment, and stopping treatment time
.
Between January 2, 1998, and November 30, 2018, 8070 patients (5594 [69-3%] men and 2476 [30.
7%] women) received 17,004 opioid agonists during 40,599 person-years treatment
.
The patients were mostly Caucasian (7006 [86.
Overall, the overall age- and sex-standardized mortality rates for suicide in the study cohort were 7.
5-fold higher than in the general population (95% CI 5.
5-10.
0)
.
Opioid agonist therapy was associated with a reduced risk of self-harm (aRR = 1.
Opioid agonist therapy was associated with a reduced risk of self-harm (aRR = 1.
Taken together, a stable period of opioid agonist therapy is associated with a reduced risk of self-harm, underscoring the importance of improving patient retention in therapy
.
The first month after discontinuation of opioid agonist therapy is a period of increased risk of suicide and self-harm, during which additional psychosocial support is required
Taken together, a stable period of opioid agonist therapy is associated with a reduced risk of self-harm, underscoring the importance of improving patient retention in therapy
references:
Self-harm and suicide during and after opioid agonist treatment among primary care patients in England: a cohort study.
Self-harm and suicide during and after opioid agonist treatment among primary care patients in England: a cohort study.
Leave a comment here
